|
Showing 1 - 5 of
5 matches in All Departments
A cutting-edge analysis of the global issues surrounding modern
reproductive technologies Advances in assisted reproductive
technologies have sparked global policy debates since the birth of
the first so-called "test tube baby" in 1978. Today, mitochondrial
replacement therapies represent the most recent advancement in
assisted reproductive technologies, allowing some women with
mitochondrial diseases to birth babies without those diseases. In
the past decade, mitochondrial replacement therapies have captured
public sentiment, reigniting debates around social views of
reproductive rights and the appropriate legal and political
response. Reproduction Reborn guides readers through the history
and science of mitochondrial replacement therapies and the various
attempts to control them. Leading experts from medicine, genetics,
ethics, law, and policy explore the influence of public debate on
the evolving shape of these technologies and their subsequent
regulation. They highlight case studies from both developed and
developing countries across the globe, including recent legislation
in Australia and China. They further identify the ethical, legal,
and societal norms that need to be addressed by policymakers and
communities as more and more people seek to gain access to these
treatments. Given the importance of reproduction in family life and
cultural identity, clinicians and policymakers must understand how
regulatory regimes around mitochondrial replacement therapies have
evolved to illuminate the processes and challenges of governing
reproduction in a fast-moving world. Informative and global in
scope, Reproduction Reborn explores how advancements in assisted
reproductive technologies challenge core values surrounding the
rights and responsibilities of modern-day family units.
Within the context of the Convention on Biological Diversity (CBD),
the Cartagena Protocol on Biosafety (CPB) was established as an
implementing agreement. The CPB is an international agreement
establishing the rights of recipient countries to be notified of
and to approve or reject the domestic import and/or production of
living modified organisms (LMOs). Decisions regarding
import/production are to be on the basis of a biosafety assessment.
Article 26.1 of the CPB allows for the (optional) inclusion of
socio-economic considerations (SECs) into that biosafety assessment
process. This book compiles expert assessments of the issues
relevant to SEC assessment of LMOs and fundamental for decisions
regarding whether to undertake such assessments at all. It includes
an overview of the inclusion of SEC assessment in the regulation of
LMOs that looks at the rationale for the inclusion of SECs, in the
context of the existing science-based risk assessment systems. This
book reviews the various factors that can and have been suggested
for inclusion in SEC assessment, and provides a meaningful dialogue
about the contrasts, benefits and tradeoffs that are, and will, be
created by the potential move to the inclusion of SECs in the
regulation of LMOs, making it of interest to both academics and
policy-makers.
Our growing ability to manufacture materials at the atomic scale
will change our lives for the better, and tomorrow's nano-economy
will outperform today's information age. Or so its proponents
claim. Others maintain that a future dominated by commercial
incentives risks a toxicological nightmare to rival the sorry
global story of asbestos. This important volume is a timely
contribution to increasing international calls to regulate
nanotechnologies. By investigating the ways in which we could
regulate these advances, and what we are learning from regulating
existing technologies, such as biotechnologies and information
technologies, the book debates the roles of government, business
actors and the professions in protecting and enhancing the lives of
citizens. In placing particular emphasis on the lessons of earlier
technology advances, this book is unique in its broad consideration
of the ethical, legal and social issues entwined within the
development of the nanotechnology family. The multi-jurisdictional
and interdisciplinary nature of the book will appeal to
governments, academics, and civil societies across many parts of
the world, while also remaining accessible to informed readers with
an interest in nanotechnology and the policy and governance issues
associated with technology development and regulation.
Within the context of the Convention on Biological Diversity (CBD),
the Cartagena Protocol on Biosafety (CPB) was established as an
implementing agreement. The CPB is an international agreement
establishing the rights of recipient countries to be notified of
and to approve or reject the domestic import and/or production of
living modified organisms (LMOs). Decisions regarding
import/production are to be on the basis of a biosafety assessment.
Article 26.1 of the CPB allows for the (optional) inclusion of
socio-economic considerations (SECs) into that biosafety assessment
process. This book compiles expert assessments of the issues
relevant to SEC assessment of LMOs and fundamental for decisions
regarding whether to undertake such assessments at all. It includes
an overview of the inclusion of SEC assessment in the regulation of
LMOs that looks at the rationale for the inclusion of SECs, in the
context of the existing science-based risk assessment systems. This
book reviews the various factors that can and have been suggested
for inclusion in SEC assessment, and provides a meaningful dialogue
about the contrasts, benefits and tradeoffs that are, and will, be
created by the potential move to the inclusion of SECs in the
regulation of LMOs, making it of interest to bothacademics and
policy-makers."
Our growing ability to manufacture materials at the atomic scale
will change our lives for the better, and tomorrow's nano-economy
will outperform today's information age. Or so its proponents
claim. Others maintain that a future dominated by commercial
incentives risks a toxicological nightmare to rival the sorry
global story of asbestos. This important volume is a timely
contribution to increasing international calls to regulate
nanotechnologies. By investigating the ways in which we could
regulate these advances, and what we are learning from regulating
existing technologies, such as biotechnologies and information
technologies, the book debates the roles of government, business
actors and the professions in protecting and enhancing the lives of
citizens. In placing particular emphasis on the lessons of earlier
technology advances, this book is unique in its broad consideration
of the ethical, legal and social issues entwined within the
development of the nanotechnology family. The multi-jurisdictional
and interdisciplinary nature of the book will appeal to
governments, academics, and civil societies across many parts of
the world, while also remaining accessible to informed readers with
an interest in nanotechnology and the policy and governance issues
associated with technology development and regulation.
|
|